Bioatla and context therapeutics announce exclusive worldwide license agreement to develop and commercialize ba3362, a nectin-4 x cd3 t cell engaging antibody

Context to obtain exclusive development and commercialization rights to ba3362 bioatla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and commercial milestones of up to $118.5 million, plus royalties on net sales context anticipated ind filing for ba3362 in mid-2026 san diego and philadelphia, sept. 23, 2024 (globe newswire) -- bioatla, inc. (“bioatla”) (nasdaq: bcab), a global clinical-stage biotechnology company focused on the development of conditionally active biologic (“cab”) antibody therapeutics for the treatment of solid tumors, and context therapeutics inc. (“context”) (nasdaq: cntx), a biopharmaceutical company advancing t cell engaging (“tce”) bispecific antibodies for solid tumors, today announced that the companies have entered into an agreement under which context has obtained from bioatla an exclusive, worldwide license to develop, manufacture and commercialize ba3362, bioatla's nectin-4 x cd3 tce.
BCAB Ratings Summary
BCAB Quant Ranking